RT Journal Article
SR Electronic
T1 Impact of clinical severity on plasma p-tau performance in predementia Alzheimer’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.06.24311532
DO 10.1101/2024.08.06.24311532
A1 Gonzalez-Ortiz, Fernando
A1 Kirsebom, Bjørn-Eivind
A1 Yakoub, Yara
A1 Gundersen, Julia K.
A1 Pålhaugen, Lene
A1 Waterloo, Knut
A1 Selnes, Per
A1 Jarholm, Jonas Alexander
A1 Gísladóttir, Berglind
A1 Rongve, Arvid
A1 Skogseth, Ragnhild Eide
A1 Bråthen, Geir
A1 Aarsland, Dag
A1 Turton, Michael
A1 Harrison, Peter
A1 Zetterberg, Henrik
A1 Villeneuve, Sylvia
A1 PREVENT AD research group
A1 Fladby, Tormod
A1 Blennow, Kaj
YR 2025
UL http://medrxiv.org/content/early/2025/01/08/2024.08.06.24311532.abstract
AB Background and objectives Detecting Alzheimer’s disease (AD) biological and clinical changes is crucial for early diagnostic and therapeutic interventions. Here we investigate the relationship between clinical severity and levels of phosphorylated tau, focusing on plasma biomarkers, in preclinical and prodromal AD.Methods In this study (n=621), we examined two independent cohorts consisting of preclinical and prodromal AD. Cohort-1 included 431 participants classified as either cognitively normal (CN) or mild cognitive impaired (MCI) with normal or abnormal cerebrospinal fluid (CSF) Aβ42/40 ratio (A) and p-tau181 (T) [CN A-/T-, n=169; A+/T-, CN=26; MCI=24; A+/T+, CN=40; MCI=105; CN=34; MCI=33]. A total of n=418 of the participants had longitudinal assessments of verbal memory up to 9.67 years from baseline. Cohort-2 included 190 participants in whom amyloid status was determined using Aβ positron emission tomography (PET) [Aβ- CN= 118; Aβ+ CN= 49; Aβ+ MCI= 21].Results In cohort-1, plasma p-tau217 showed a moderate correlation with its corresponding CSF biomarker (rho=0.65, p<.001) and high accuracy identifying Aβ+ participants (AUC: 0.85). Diagnostic accuracy of plasma p-tau217 was significantly greater for MCI Aβ+ (AUC: 0.89) versus CN Aβ+ (AUC: 0.79, p<.05) and for A+/T+ (AUC: 0.88) versus A+/T- (AUC: 0.78, p<.05). P-tau181 and p-tau231 showed significantly weaker CSF-plasma correlations (rho= 0.47, and rho=0.32, p<.001, respectively) and levels were not as tightly associated with cognitive status in the Aβ+ group. While all the CSF p-tau markers were associated to future cognitive deterioration, p-tau217 was the only plasma biomarker associated with future memory decline (β=0.05, p<0.05). In cohort 1 and 2, plasma p-tau217 showed significantly higher concentrations in MCI Aβ+ as compared to CN Aβ+. Furthermore, plasma p-tau217 demonstrates similar biomarker elevations when compared to CN Aβ- controls in both cohorts.Discussion Our findings indicate that, unlike p-tau181 and p-tau231, plasma p-tau217 consistently aligns with cognitive status in Aβ+ individuals and more closely reflects CSF biomarker abnormalities, potentially reducing discrepancies between clinical and biochemical findings. The associations of plasma p-tau217 with baseline and future cognitive decline make it a valuable complement to clinical evaluations in preclinical and prodromal AD, especially when CSF analysis or PET are not feasible.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthors funding information is provided in the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymized aggregated level data will be shared by request from a qualified academic investigator for the sole purpose of replicating procedures and results presented in the article, and as long as data transfer is in agreement with EU legislation on the general data protection regulation and decisions by the Ethical Review Boards in charge of each of the cohorts used for this study.